| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 11/17/2005 | WO2005108401A1 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones |
| 11/17/2005 | WO2005108400A1 Pyridoquinazoline derivatives having heterobicyclic substituents |
| 11/17/2005 | WO2005108399A1 Imidazopyridine compound |
| 11/17/2005 | WO2005108398A1 6-substituted pyridoindolone derivatives production and therapeutic use thereof |
| 11/17/2005 | WO2005108396A1 Therapeutic agent for keratoconjunctiva disorder |
| 11/17/2005 | WO2005108393A1 Pyrrole or imidazole amides for treating obesity |
| 11/17/2005 | WO2005108392A2 Process for preparing ondansetron hydrochloride dihydrate having a defined particle size |
| 11/17/2005 | WO2005108389A1 Indole derivatives having piperidine rings |
| 11/17/2005 | WO2005108388A1 Pyridine derivatives of alkyl oxindoles as 5-ht7 receptor active agents |
| 11/17/2005 | WO2005108387A2 Cytokine inhibitors |
| 11/17/2005 | WO2005108384A1 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands |
| 11/17/2005 | WO2005108382A1 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 11/17/2005 | WO2005108378A2 Use of (4-alkylpiperazinyl) (phenyl) methanones in the treatment of alzheimer’s disease |
| 11/17/2005 | WO2005108376A1 Calcilytic compounds |
| 11/17/2005 | WO2005108375A1 Process for the preparation of telmisartan |
| 11/17/2005 | WO2005108370A1 Benzene compounds |
| 11/17/2005 | WO2005108367A1 Compounds for treatment of neurodegenerative diseases |
| 11/17/2005 | WO2005108364A1 Piperazine derivatives of alkyl oxindoles |
| 11/17/2005 | WO2005108363A1 Piperazine derivatives of alkyl oxindoles |
| 11/17/2005 | WO2005108359A1 Novel compounds of proline and morpholine derivatives |
| 11/17/2005 | WO2005108355A2 Dihydrobenzothiophenes |
| 11/17/2005 | WO2005108354A1 Use of biphenyl-derived thiamides as calpain inhibitors |
| 11/17/2005 | WO2005108352A1 Novel biaromatic compounds which activate pparϝ-type receptors, their process of preparation and their use in cosmetic or pharmaceutical compositions |
| 11/17/2005 | WO2005108349A2 Process for preparing atazanavir bisulfate and novel forms |
| 11/17/2005 | WO2005108338A1 Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders |
| 11/17/2005 | WO2005108337A2 Compounds with activity at estrogen receptor |
| 11/17/2005 | WO2005107875A2 Triglycerides, fatty acids, alcohols as cns modulators |
| 11/17/2005 | WO2005107874A2 Use of pirinixinic acid and the salts thereof for treating chronic inflammatory diseases |
| 11/17/2005 | WO2005107873A2 Glycopyrrolate for treating childhood asthma |
| 11/17/2005 | WO2005107872A2 Treating respiratory diseases with gycopyrrolate and analogues |
| 11/17/2005 | WO2005107871A2 Pyrroloquinoline quinone drugs for treatment of cardiac injury |
| 11/17/2005 | WO2005107812A1 Permeation enhancing compositions for anticholinergic agents |
| 11/17/2005 | WO2005107810A2 Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
| 11/17/2005 | WO2005107809A2 Antimycobacterial pharmaceutical composition comprising an antitubercular drug |
| 11/17/2005 | WO2005107808A2 Combination of atypical antipsychotics and 5-ht1b receptor antagonists |
| 11/17/2005 | WO2005107807A2 Cerebral intraventricular transplantation as method of treating amyotrophic lateral sclerosis |
| 11/17/2005 | WO2005107805A1 Aβ-PRODUCTION INHIBITOR |
| 11/17/2005 | WO2005107804A1 Therapeutic agent for respiratory ailment |
| 11/17/2005 | WO2005107801A2 Systems and methods for treating human inflammatory and proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors and/or ucp and/or fas antibodies |
| 11/17/2005 | WO2005107792A2 Compositions and methods for treatment of protein misfolding diseases |
| 11/17/2005 | WO2005107791A1 Medicament for the treatment of fungal infections, particularly aspergillosis |
| 11/17/2005 | WO2005107788A1 Inhibition of allergic contact dermatitis by n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester |
| 11/17/2005 | WO2005107779A2 Weight loss composition and method of inducing weight loss |
| 11/17/2005 | WO2005107773A2 Solid dosage form of wetted heparin |
| 11/17/2005 | WO2005107772A1 Composition for stimulating bone growth and differentiation and method for isolating same |
| 11/17/2005 | WO2005107771A2 Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer |
| 11/17/2005 | WO2005107770A1 Use of equol for treating skin diseases |
| 11/17/2005 | WO2005107769A1 Oral flora-improving agent, antibacterial agent and growth promoter |
| 11/17/2005 | WO2005107768A2 Method for improving ventilatory efficiency |
| 11/17/2005 | WO2005107767A2 Modulation of lysophosphatidylcholine and treatment of diet-induced conditions |
| 11/17/2005 | WO2005107766A1 Phospholipase inhibitors localized in the gastrointestinal lumen |
| 11/17/2005 | WO2005107765A2 Heart treatment method |
| 11/17/2005 | WO2005107764A1 Perfluorocarbon-soluble compounds |
| 11/17/2005 | WO2005107763A2 Radiopharmaceutical and methods of synthesis and use thereof |
| 11/17/2005 | WO2005107762A2 Certain chemical entities, compositions, and methods |
| 11/17/2005 | WO2005107761A1 Sustained-release oral molsidomine composition for treating atherosclerosis |
| 11/17/2005 | WO2005107760A1 Compounds and compositions as inducers of keratinocyte differentiation |
| 11/17/2005 | WO2005107759A1 Bh4-responsive hyperphenylalaninemia remedies |
| 11/17/2005 | WO2005107758A1 4-phenylamino-quinazolin-6-yl-amides |
| 11/17/2005 | WO2005107757A2 A method for the prevention of thromboembolic disorders |
| 11/17/2005 | WO2005107756A1 A method for the treatment or prevention of cardiac hypertrophy |
| 11/17/2005 | WO2005107755A1 Process for the production of contraceptive formulations |
| 11/17/2005 | WO2005107754A2 Transdermal iontophoretic delivery of piperazinyl-2(3h)-benzoxazolone compounds |
| 11/17/2005 | WO2005107753A2 Naltrexone long acting formulations and methods of use |
| 11/17/2005 | WO2005107752A2 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin |
| 11/17/2005 | WO2005107751A1 Methods for treating arthritic conditions in dogs |
| 11/17/2005 | WO2005107750A1 Controlled release metformin compositions |
| 11/17/2005 | WO2005107749A1 Use of roflumilast for the prophylaxis or treatment of emphysema |
| 11/17/2005 | WO2005107748A2 Method of tonic treatment with oxyphenbutazone derivatives |
| 11/17/2005 | WO2005107747A2 Diindolymethane formulations for the treatment of leiomyomas |
| 11/17/2005 | WO2005107746A1 Pharmaceutical composition for prevention or treatment of lipid metabolism disorder |
| 11/17/2005 | WO2005107745A1 An inhibitor of hepatitis c |
| 11/17/2005 | WO2005107744A1 Nerve damage |
| 11/17/2005 | WO2005107743A1 Compounds and compositions for treatment of cancer |
| 11/17/2005 | WO2005107742A1 Novel antiviral helioxanthin analogs |
| 11/17/2005 | WO2005107741A1 Novel oral compositions comprising antitubercular drugs in combination with alpha-tocopherol |
| 11/17/2005 | WO2005107740A1 Enhancing the efficacy of tubercular drugs by combination with alpha tocopherol |
| 11/17/2005 | WO2005107739A1 Spiroderivatives for the treatment of hypertension |
| 11/17/2005 | WO2005107738A2 Basic amino acid-methionine hydroxy analog compositions |
| 11/17/2005 | WO2005107737A1 Antifatigue composition |
| 11/17/2005 | WO2005107736A1 Cla-enriched milkfat and uses thereof |
| 11/17/2005 | WO2005107735A2 Nutritional composition for enhancing lean muscle stimulus, growth, strength and recovery, creating and prolonging intense muscle pumps, supporting endurance, strength, performance, size and stamina, providing a transducer effect for nitric oxide, incresing nutrient delivery and/or promoting increased vascular response in a |
| 11/17/2005 | WO2005107734A1 Alcohol metabolism accelerating composition, and food or drink containing the composition |
| 11/17/2005 | WO2005107733A1 Dermatological external preparation for local anesthesia |
| 11/17/2005 | WO2005107732A1 Topical preparation containing ambroxol |
| 11/17/2005 | WO2005107731A1 Remedies containing vitamin k2 as the active ingredient |
| 11/17/2005 | WO2005107730A2 Cysteamines for treating complications of hypercholesterolemia and diabetes |
| 11/17/2005 | WO2005107729A1 Compositions comprising lycopene and phytoestrogen |
| 11/17/2005 | WO2005107728A2 Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity |
| 11/17/2005 | WO2005107727A1 Steroid intraocular implants having an extended sustained release for a period of greater than two months |
| 11/17/2005 | WO2005107726A2 Method for the treatment of back pain |
| 11/17/2005 | WO2005107725A1 Use of ltb4 inhibitors for the treatment of b-cell leukemias and lymphomas |
| 11/17/2005 | WO2005107724A1 Treatment of apoptosis |
| 11/17/2005 | WO2005107719A2 Pharmaceutical composition comprising hydrophobic drug having improved solubility |
| 11/17/2005 | WO2005107718A1 Anti-excitotoxic sustained release intraocular implants and related methods |
| 11/17/2005 | WO2005107717A2 Oral dosage form for the extended release of biguanide and sulfonylurea |
| 11/17/2005 | WO2005107716A1 Controlled release paroxetine-containing tablets based on a core and a coating |
| 11/17/2005 | WO2005107714A2 Method of forming microparticles that include a bisphosphonate and a polymer |
| 11/17/2005 | WO2005107713A2 Swellable dosage form comprising gellan gum |
| 11/17/2005 | WO2005107711A2 Method and composition for treating rhinitis |